|
US20030157161A1
(en)
*
|
2001-05-01 |
2003-08-21 |
Angiotech Pharmaceuticals, Inc. |
Compositions and methods for treating inflammatory conditions utilizing protein or polysaccharide containing anti-microtubule agents
|
|
WO2002087563A2
(en)
*
|
2001-05-01 |
2002-11-07 |
Angiotech Pharmaceuticals Inc. |
Compositions comprising an anti-microtubule agent and a polypeptide or a polysaccharide and the use thereof for the preparation of a medicament for the treatment of inflammatory conditions
|
|
US7354574B2
(en)
|
2002-11-07 |
2008-04-08 |
Advanced Ocular Systems Limited |
Treatment of ocular disease
|
|
FR2848106B1
(fr)
*
|
2002-12-06 |
2006-11-17 |
Oreal |
Composition de teinture pour fibres keratiniques comprenant un alcool gras non oxyalkylene, un colorant d'oxydation, un polymere associatif et un amide d'une alcanolamine et d'un acide gras en c14-c30.
|
|
US7326256B2
(en)
*
|
2002-12-06 |
2008-02-05 |
L'ORéAL S.A. |
Composition for the oxidation dyeing of keratin fibers, comprising at least one non-oxyalkenylated fatty alcohol, at least one oxidation dye, at least one associative polymer, and at least one amide of an alkanolamine and a C14-C30 fatty acid
|
|
JP2004262777A
(ja)
*
|
2003-02-27 |
2004-09-24 |
Shiseido Co Ltd |
アセチル化ヒアルロン酸含有眼用医薬組成物
|
|
US20050196370A1
(en)
*
|
2003-03-18 |
2005-09-08 |
Zhi-Jian Yu |
Stable ophthalmic oil-in-water emulsions with sodium hyaluronate for alleviating dry eye
|
|
WO2004096261A1
(es)
*
|
2003-05-02 |
2004-11-11 |
Arturo Jimenez Bayardo |
Metodo para preparar una solucion acuosa de ciclosporina-a y solucion acuosa resultante
|
|
US7947295B2
(en)
*
|
2003-06-13 |
2011-05-24 |
Alcon, Inc. |
Ophthalmic compositions containing a synergistic combination of two polymers
|
|
US7083802B2
(en)
|
2003-07-31 |
2006-08-01 |
Advanced Ocular Systems Limited |
Treatment of ocular disease
|
|
US7087237B2
(en)
|
2003-09-19 |
2006-08-08 |
Advanced Ocular Systems Limited |
Ocular solutions
|
|
US7083803B2
(en)
|
2003-09-19 |
2006-08-01 |
Advanced Ocular Systems Limited |
Ocular solutions
|
|
EP1706095B1
(en)
*
|
2004-01-20 |
2008-12-24 |
Allergan, Inc. |
Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
|
|
US7135455B2
(en)
*
|
2004-11-15 |
2006-11-14 |
Allergan, Inc |
Methods for the therapeutic use of cyclosporine components
|
|
WO2006067608A1
(en)
*
|
2004-12-22 |
2006-06-29 |
Laboratoire Medidom S.A. |
Aqueous formulations based on sodium hyaluronate for parenteral use
|
|
US8663639B2
(en)
|
2005-02-09 |
2014-03-04 |
Santen Pharmaceutical Co., Ltd. |
Formulations for treating ocular diseases and conditions
|
|
EP1848431B1
(en)
|
2005-02-09 |
2016-02-03 |
Santen Pharmaceutical Co., Ltd. |
Liquid formulations for treatment of diseases or conditions
|
|
CN100478025C
(zh)
*
|
2005-03-25 |
2009-04-15 |
中国科学院上海药物研究所 |
一种环孢菌素a眼用微乳制剂及其制备方法
|
|
EP1906949B1
(en)
*
|
2005-07-01 |
2015-02-11 |
SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. |
Use of l-carnitine or of alkanoyl l-carnitines for the preparation of a physiological supplement or medicament for ophthalmic use in the form of eye-drops
|
|
US20070014760A1
(en)
*
|
2005-07-18 |
2007-01-18 |
Peyman Gholam A |
Enhanced recovery following ocular surgery
|
|
CA2615990A1
(en)
|
2005-07-18 |
2007-01-25 |
Minu, L.L.C. |
Enhanced ocular neuroprotection/neurostimulation
|
|
US7501393B2
(en)
*
|
2005-07-27 |
2009-03-10 |
Allergan, Inc. |
Pharmaceutical compositions comprising cyclosporins
|
|
AU2006300207C1
(en)
|
2005-10-12 |
2012-05-24 |
Seikagaku Corporation |
Agent for applying to mucosa and method for production thereof
|
|
US9839667B2
(en)
|
2005-10-14 |
2017-12-12 |
Allergan, Inc. |
Prevention and treatment of ocular side effects with a cyclosporin
|
|
US7745400B2
(en)
*
|
2005-10-14 |
2010-06-29 |
Gregg Feinerman |
Prevention and treatment of ocular side effects with a cyclosporin
|
|
CN101355876B
(zh)
|
2005-11-09 |
2012-09-05 |
康宾纳特克斯公司 |
一种适用于眼部给药的组合物
|
|
ES2612196T3
(es)
*
|
2005-12-13 |
2017-05-12 |
Incyte Holdings Corporation |
Pirrolo[2,3-b]piridinas y pirrolo[2,3-b]pirimidinas sustituidas con heteroarilo como inhibidores de quinasas Janus
|
|
WO2007092620A2
(en)
|
2006-02-09 |
2007-08-16 |
Macusight, Inc. |
Stable formulations, and methods of their preparation and use
|
|
US7655625B2
(en)
|
2006-02-13 |
2010-02-02 |
Allergan, Inc. |
Methods of treating blepharospasm using cyclosporine components
|
|
US20070212420A1
(en)
*
|
2006-03-10 |
2007-09-13 |
Bausch & Lomb Incorporated |
Pharmaceutical formulations comprising polyanionic materials and zinc-based preservatives
|
|
PL2001466T3
(pl)
|
2006-03-23 |
2016-06-30 |
Santen Pharmaceutical Co Ltd |
Rapamycyna w małej dawce do leczenia chorób związanych z przepuszczalnością naczyń
|
|
WO2008002582A2
(en)
*
|
2006-06-27 |
2008-01-03 |
Riolan Technologies, Inc. |
Ultraviolet absorbing ophthalmic compositions
|
|
US9561178B2
(en)
*
|
2006-07-25 |
2017-02-07 |
Allergan, Inc. |
Cyclosporin compositions
|
|
AU2016203191B2
(en)
*
|
2006-07-25 |
2018-03-01 |
Allergan, Inc. |
Cyclosporin compositions
|
|
WO2008035246A2
(en)
|
2006-07-28 |
2008-03-27 |
Novagali Pharma Sa |
Compositions containing quaternary ammonium compounds
|
|
CN101896160A
(zh)
*
|
2006-10-17 |
2010-11-24 |
阿勒根公司 |
环胞菌素组合物
|
|
CN101678034A
(zh)
*
|
2007-03-30 |
2010-03-24 |
佛维雅制药股份有限公司 |
治疗新血管眼病的方法
|
|
EP2173752B2
(en)
|
2007-06-13 |
2022-07-13 |
Incyte Holdings Corporation |
Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
|
|
CN101918019B
(zh)
|
2007-10-08 |
2014-11-26 |
奥里尼亚制药有限公司 |
包含钙调神经磷酸酶抑制剂或mTOR抑制剂的眼科组合物
|
|
EP2195033A1
(en)
*
|
2007-10-08 |
2010-06-16 |
Fovea Pharmaceuticals SA |
Aqueous ophthalmic formulations
|
|
US20100016219A1
(en)
*
|
2008-07-19 |
2010-01-21 |
Jerry Zhang |
Ophthalmic compositions containing solubilized cyclosporin
|
|
CL2009001884A1
(es)
*
|
2008-10-02 |
2010-05-14 |
Incyte Holdings Corp |
Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
|
|
GB0904423D0
(en)
*
|
2009-03-14 |
2009-04-29 |
Univ Strathclyde |
Improving the solubility of chemicals
|
|
US8716303B2
(en)
|
2009-05-22 |
2014-05-06 |
Incyte Corporation |
N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
|
TWI484962B
(zh)
|
2009-05-22 |
2015-05-21 |
Incyte Corp |
作為ｊａｋ抑制劑之３－〔４－（７ｈ－吡咯并〔２，３－ｄ〕嘧啶－４－基）－１ｈ－吡唑－１－基〕辛烷或庚腈
|
|
CN102458370A
(zh)
*
|
2009-06-09 |
2012-05-16 |
卢克斯生物科技公司 |
用于眼科用途的表面药物递送***
|
|
US9249145B2
(en)
|
2009-09-01 |
2016-02-02 |
Incyte Holdings Corporation |
Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
|
KR102354472B1
(ko)
|
2010-03-10 |
2022-01-21 |
인사이트 홀딩스 코포레이션 |
Ｊａｋ１ 저해제로서의 피페리딘４일 아제티딘 유도체
|
|
EP2574168B9
(en)
|
2010-05-21 |
2016-10-05 |
Incyte Holdings Corporation |
Topical formulation for a jak inhibitor
|
|
WO2012068450A1
(en)
|
2010-11-19 |
2012-05-24 |
Incyte Corporation |
Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
|
|
JP5917544B2
(ja)
|
2010-11-19 |
2016-05-18 |
インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ |
Ｊａｋ阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン
|
|
JP5876146B2
(ja)
|
2011-06-20 |
2016-03-02 |
インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ |
Ｊａｋ阻害剤としてのアゼチジニルフェニル、ピリジル、またはピラジニルカルボキサミド誘導体
|
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
|
|
UA111854C2
(uk)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки для отримання інгібіторів jak
|
|
BR112014011744A2
(pt)
*
|
2011-11-15 |
2017-05-02 |
Allergan Inc |
formulação de ação sustentável da forma 2 de ciclosporina
|
|
CN104039308B
(zh)
*
|
2011-11-15 |
2018-06-05 |
阿勒根公司 |
环孢菌素a形式2的可热压性悬浮液
|
|
FR2988297B1
(fr)
*
|
2012-03-22 |
2014-03-28 |
Thea Lab |
Solution ophtalmique aqueuse a base de ciclosporine a sans conservateur
|
|
AR091079A1
(es)
|
2012-05-18 |
2014-12-30 |
Incyte Corp |
Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak
|
|
HUE055894T2
(hu)
|
2012-11-15 |
2021-12-28 |
Incyte Holdings Corp |
A ruxolitinib nyújtott felszabadulású dózisformái
|
|
PE20151902A1
(es)
|
2013-03-06 |
2015-12-26 |
Incyte Corp |
Proceso e intermedios para hacer un inhibidor de jak
|
|
US9492474B2
(en)
|
2013-07-10 |
2016-11-15 |
Matrix Biology Institute |
Compositions of hyaluronan with high elasticity and uses thereof
|
|
EP3721873A1
(en)
|
2013-08-07 |
2020-10-14 |
Incyte Corporation |
Sustained release dosage forms for a jak1 inhibitor
|
|
WO2015184305A1
(en)
|
2014-05-30 |
2015-12-03 |
Incyte Corporation |
TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
|
|
KR20170030093A
(ko)
*
|
2014-07-18 |
2017-03-16 |
알레간 인코포레이티드 |
결막하 및 눈주위 주사를 위한 사이클로스포린 a의 현탁액 조성물
|
|
PT3352766T
(pt)
|
2015-09-24 |
2022-03-22 |
Matrix Biology Inst |
Composições de hialuronano de elevada elasticidade e processos para o seu uso
|
|
KR101635915B1
(ko)
*
|
2016-02-15 |
2016-07-04 |
삼천당제약주식회사 |
사이클로스포린과 히알루론산 또는 이의 염을 포함하는 수용액 형태의 안과용 조성물
|
|
KR20190068575A
(ko)
*
|
2016-10-14 |
2019-06-18 |
이콤 메디칼 게엠베하 |
안구 표면 항상성의 확립, 회복 및 보존 방법
|
|
US20190224275A1
(en)
|
2017-05-12 |
2019-07-25 |
Aurinia Pharmaceuticals Inc. |
Protocol for treatment of lupus nephritis
|
|
US11766421B2
(en)
|
2017-09-25 |
2023-09-26 |
Surface Ophthalmics, Inc. |
Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease
|
|
AR113922A1
(es)
|
2017-12-08 |
2020-07-01 |
Incyte Corp |
Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
|
|
DK3746429T3
(da)
|
2018-01-30 |
2022-05-02 |
Incyte Corp |
Fremgangsmåder til fremstilling af (1-(3-fluor-2-(trifluormethyl)isonicotinyl)piperidin-4-on)
|
|
EP3773330A4
(en)
*
|
2018-03-29 |
2022-01-05 |
Mati Therapeutics Inc. |
FORMULATION ON DELAYED RELEASE OF OPHTHALMIC MEDICINAL PRODUCTS AND USES FOR TREATMENT OF DRY EYE
|
|
IL277538B1
(en)
|
2018-03-30 |
2024-05-01 |
Incyte Corp |
Use of JAK inhibitors to treat hidradenitis suppurativa
|
|
SG11202106967QA
(en)
*
|
2018-12-27 |
2021-07-29 |
Surface Ophthalmics Inc |
Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease
|
|
US20220378698A1
(en)
|
2019-07-12 |
2022-12-01 |
Pharmathen S.A. |
Preservative free pharmaceutical composition for ophthalmic administration containing cyclosporine
|
|
MX2022006176A
(es)
|
2019-11-22 |
2022-08-17 |
Incyte Corp |
Terapia combinada que comprende un inhibidor de alk2 y un inhibidor de jak2.
|
|
CA3173164A1
(en)
*
|
2020-03-23 |
2021-09-30 |
Brenda K. Mann |
Compositions and methods for treatment of ocular conditions
|
|
GR1010012B
(el)
|
2020-05-12 |
2021-05-27 |
Φαρματεν Α.Β.Ε.Ε. |
Φαρμακευτικο σκευασμα ελευθερο συντηρητικου για οφθαλμικη χορηγηση περιεχον κυκλοσπορινη
|
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
|
US11510930B2
(en)
*
|
2020-08-26 |
2022-11-29 |
Somerset Therapeutics, Llc |
Gatifloxacin, prednisolone, and bromfenac compositions and methods
|
|
WO2024019127A1
(ja)
*
|
2022-07-20 |
2024-01-25 |
旭化成株式会社 |
ヒアルロン酸誘導体医薬組成物及び医薬組成物の製造方法
|